Study S002233

A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07728383
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 40
Start: 2026-06-17
Primary completion: 2027-05
Lead sponsor: Gila Therapeutics, Inc.
Conditions: Obesity & Overweight
Interventions: DRUG:Semaglutide 6 mg liquid emulsion formulation; DRUG:Wegovy® (semaglutide) Tablet; DRUG:Placebo liquid emulsion formulation
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent body weight change from baseline [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.